Myrmecia (ant) encountered before. Based on five species, the median lethal dose (LD) is 0.18–0.35 mg/kg, making it among the most toxic venoms in the insect world. The toxicity of the venom may have evolved due to the intense predation by animals and birds during the day, since "Myrmecia" is primarily diurnal. In Tasmania, 2–3% of the human population is allergic to "M. pilosula" venom. In comparison, only 1.6% people are allergic to the venom of the western honeybee ("Apis mellifera"), and 0.6% to the venom of the European wasp ("Vespula germanica"). In a 2011 Australian ant-venom allergy study, the objective of
Jack jumper ant thirty with a history of severe allergic reactions would greatly benefit from venom immunotherapy. Both rapid and slow doses can be done safely during immunotherapy. The efficacy (capacity to induce a therapeutic effect) of ant venom immunotherapy is effective in reducing systemic reactions in comparison to placebo and whole body extract immunotherapy, where patients were more likely to suffer from a systemic reaction. Ultrarush initiation of insect immunotherapy may be used, but results show higher risks of allergic reactions. Despite immunotherapy being successful, only ten percent of patients do not have any response to desensitisation. It is suggested that people